Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)

Liver International

Volumn 37, Issue , 2017, Pages 45-51

  Grossi, Glenda ^a   Viganò, Mauro ^a   Loglio, Alessandro ^a   Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

cirrhosis; hepatitis B; hepatocellular carcinoma; nucleot(s)ides analogues

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; GUANINE; HEPATITIS B(E) ANTIGEN; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BIOCHEMICAL ANALYSIS; BONE DENSITY; CANCER PREVENTION; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; FATTY LIVER; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HYPERLACTATEMIA; INFECTION PREVENTION; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MANAGED CARE; MEGALOCYTOSIS; MULTICENTER STUDY (TOPIC); MYOPATHY; NEPHROTOXICITY; NEUROPATHY; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEROLOGY; SIDE EFFECT; SURVIVAL RATE; TREATMENT RESPONSE; VIROLOGY; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DRUG EFFECTS; LIVER TUMOR; QUALITY OF LIFE; SAFETY; SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; SUSTAINED VIROLOGIC RESPONSE; TENOFOVIR;

EID: 85007609310     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13291     Document Type: Review

References (56)

1. Stasi C, Silvestri C, Voller F, et al. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health. 2016;9:389–395.
2. Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection – EASL Special Conference. J Hepatol. 2015;63:1238–1253.
3. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
4. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.
5. Chang TT, Lai CL, Kew Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–430.
6. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–1514.
7. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
8. Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology. 2014;60:A229.
9. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240–1248.
10. Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289–1295.
11. Lampertico P, Soffredini R, Viganò M, et al. 5-Year entecavir treatment in NUC-naive, field practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis. J Hepatol. 2013;58:S306.
12. Seto WK, Lam YF, Fung J, et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29:1028–1034.
13. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t) ide-naıve chronic hepatitis B patients. J Hepatol. 2012;57:508–514.
14. Luo J, Li X, Wu Y, et al. Efficacy of entecavir treatment for up 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427–433.
15. Tanwandee T, Charatcharoenwitthaya P, Chainuvati S, et al. Efficacy and safety of entecavir treatment of chronic hepatitis B patients in real-world clinical practice. Hepatology. 2013;58:672A.
16. Petersen J, Heyne R, Mauss S, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci. 2016;61:3061–3071. [Epub ahead of print].
17. Tabernero D, Sánchez-Tapias JM, Calleja JL, et al. Long-term efficacy of tenofovir in previously treated and naïve patients. Results from the Spanish Chronic Hepatitis B Registry (CIBERHEP). J Hepatol. 2014;60:S429.
18. Marcellin P, Zoulim F, Hézode C. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;61:3072–3083.
19. Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Hepatology. 2013;58:A933.
20. Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63:1481–1492.
21. Fung S, Kwan P, Fabri M, et al. Tenofovir disoproxil fumarate (TDF) versus TDF/emtricitabine (FTC) in lamivudine-resistant hepatitis B: a 5-year randomized study. J Hepatol. 2016; doi: 10.1016/j.jhep.2016.08.008. [Epub ahead of print].
22. Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042–1051.
23. Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016; doi: 10.1016/S2468-1253(16)30107-8 [Epub ahead of print].
24. Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016; doi: http://dx.doi.org/10.1016/S2468-1253(16)30024-3 [Epub ahead of print].
25. Chang TT, Liaw Y-F, Wu SS, et al. Long-term entecavir therapy results in reversal fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients. Hepatology. 2010;52:886–937.
26. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274–276.
27. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
28. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100.
29. Liaw YF, Sheen IS, Lee CM, et al. Tenofovirdisoproxilfumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.
30. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547.
31. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–765.
32. Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147:152–161.
33. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62:363–370.
34. Lampertico P, Invernizzi F, Viganò M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63:1118–1125.
35. Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol. 2013;19:6849–6856.
36. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.
37. Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933–944.
38. Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63:1943–1950.
39. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800–806.
40. Chen Y-C, Jeng W-J, Chien R-N, et al. Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment. J Hepatol. 2013;58:S214.
41. Papatheodoridis G, Manolakopoulos S, Touloumi G, et al. Hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe−) with or without cirrhosis treated with entecavir: results of the nationwide HepNet Greece Cohort Study. J Hepatol. 2013;58:S312.
42. Papatheodoridis GV, Chan HL-Y, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956–967.
43. Kim WR, Berg T, Loomba R, et al. Long-term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol. 2013;58:S19.
44. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88.
45. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660–1665.
46. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–574.
47. Lampertico P, Chan HLY, Janssen HLA, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44:16–34.
48. Conti F, Vitale G, Cursaro C, Bernardi M, Andreone P. Tenofovir-induced Fanconi syndrome in a patient with chronic hepatitis B monoinfection. Ann Hepatol. 2016;15:273–276.
49. Magalhães-Costa P, Matos L, Barreiro P, Chagas C. Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir. Rev Esp Enferm Dig. 2015;107:512–514.
50. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001–2006.
51. Miquel M, Núñez Ó, Trapero-Marugán M, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol. 2013;12:205–212.
52. Buti M, Morillas RM, Prieto M, et al. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2012;24:535–542.
53. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–451.
54. Hou JL, Jia JD, Wei L, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a “real-world” clinical practice setting in China. J Viral Hepat. 2013;20:811–820.
55. Su TH, Hu TH, Chen CY, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events, and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764.
56. Papatheodoridis G, Dalekos G, Yurdaydin C, et al. Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC). J Hepatol. 2015;62:S263–S264.